CLINICAL AND ECONOMIC CONSEQUENCES OF SWITCHING FROM OMALIZUMAB TO MEPOLIZUMAB IN UNCONTROLLED SEVERE EOSINOPHILIC ASTHMA.

(Carpagnano GE, Resta E, Povero M, Pelaia C, D’Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro – Sci Rep. 2021 Mar)

.